Related Experiment Video

Updated: Mar 10, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K

Next Generation DNA Damage Response Inhibitors: Harnessing Nanocarriers and Tumor Microenvironment for Precision

Abhishikt David Solomon1, Himanshu Kumar Vats2, Shivam Chowdhary3

  • 1Division of Oral and Craniofacial Health Sciences, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Oncology Research
|March 9, 2026
PubMed

Insights

Next-generation DNA damage response (DDR) inhibitors and nanomedicines offer improved cancer therapy. These approaches target resistance mechanisms and the tumor microenvironment for more effective, durable treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • The DNA damage response (DDR) is crucial for tumor survival, genomic stability, and therapy resistance.
  • While poly (ADP-ribose) polymerase (PARP) inhibitors target DDR, tumors develop resistance through adaptive repair and microenvironmental factors.

Purpose of the Study:

  • To review recent advancements in key DDR pathways and next-generation inhibitors.
  • To analyze the influence of the tumor microenvironment on DDR dependency and treatment response.
  • To explore novel nanocarrier-based delivery systems for enhanced cancer therapy.

Main Methods:

  • Synthesis of recent discoveries in DDR pathways including PARP, ATR, ATM, CHK1, WEE1, and DNA-PK.
  • Analysis of tumor microenvironment factors like hypoxia, inflammation, and immune cells.
  • Review of nanocarrier-based delivery systems and combination strategies.

Main Results:

  • Next-generation inhibitors demonstrate increased selectivity and potential to circumvent resistance.
  • Tumor microenvironment components significantly impact DDR dependency and therapeutic outcomes.
  • Nanomedicines enhance drug delivery, target resistant niches, and enable combinatorial therapies.

Conclusions:

  • Next-generation DDR inhibitors and nanomedicines represent a promising strategy for overcoming cancer therapy resistance.
  • Integrating DDR inhibitors with immunotherapies and radiotherapies, guided by microenvironmental context, can improve treatment efficacy.
  • These advancements pave the way for more precise, durable, and personalized cancer treatments.
Keywords:
DDR inhibitors (DDRis)DNA damage response (DDR)tumor microenvironment

More Related Videos

Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy09:01

Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy

Published on: May 22, 2020

3.6K
Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

15.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
71
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
60
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K